The Nanosensors Laboratory of the Rovira I Virgili University in collaboration with the spin-off CreatSens Health SL, the nephrology group and the CORE laboratories of the Hospital Clínic of Barcelona (Catalonia, Spain) present a validation study of a portable device for the measurement of potassium in blood in dialysis patients. The team has developed a device for the measurement of potassium, a cardiovascular and renal indicator, which does so quickly and easily and is low cost. Researchers at the URV and the Clínic have worked together to validate the measurement of potassium in renal patients during the month of December 2017 and January 2018 at the dialysis center of the Hospital Clínic in which they have analyzed more than 700 patient samples. kidney
The aim of the CreatSens project is to monitor the progress of chronic kidney disease through state-of-the-art technological tools that allow the measurement of relevant parameters for patients in a much simpler way than the current one. The vision of CreatSens is that the information generated by the measurement device can be followed from a mobile device such as a phone or a tablet, in the doctor’s office or in the patient’s home.
The scientific research is led by the researcher of the Department of Analytical Chemistry and Organic Chemistry and member of the company derived from the URV, Francisco Andrade, who points out that the technology used is based on low-cost materials (such as paper) for ” allow access of these devices to all patients. ” Adrià Maceira, CEO of CreatSens Health SL, highlights the impact of this type of tools and strategies “for the control of health in society”. The technology developed would allow the decentralized and real-time generation of relevant clinical information, which would help the nephrologist in his decision making and could contribute to optimizing the resources of the health system.
“We have obtained good results, and its usefulness will be increasing in the coming years,” says Francesc Maduell, head of the dialysis section of Hospital Clínic. His counterpart and collaborator, Miquel Blasco, comments on the importance of this type of medical devices that allow obtaining information at the moment and help clinicians to give more specific diagnoses according to the pathology of the patient. The nephrology service, together with the CORE laboratory, with the participation of Josep Lluís Bedini and Nayra Rico, have joined efforts in the validation of these new leading technologies. They are seen, increasingly, as the future trend of personalized medicine.
The CreatSens project got the support of the Iñigo Álvarez de Toledo Renal Foundation in 2017 to propose solutions to the management of chronic kidney disease with simple and inexpensive tools. The devices are low cost, they initially measure potassium, and in a second phase, they will also measure creatinine and other markers relevant to kidney function.
The Rovira I Virgili University, through its Valorization and Commercialization Unit, which has the support of ACCIÓ and the Chair on the Promotion of Entrepreneurship and the Creation of Companies, promoted the creation of the spin-off CreatSens Health SL. (Source: URV)